YNBY International Limited announced that the board of directors of the company announces that: Mr. Wong Hin Wing (Mr. Wong), MH, has been appointed as an independent non- executive director, the chairman of the audit committee (the Audit Committee) and a member of the remuneration committee (the Remuneration Committee) and the nomination committee (the Nomination Committee) with effect from 21 November 2023; Dr. Cheung Hoi Yu (Dr. Yu), JP, has been appointed as an independent non-executive director, the chairman of the Remuneration Committee and a member of the Audit Committee and the Nomination Committee with effect from 21 November 2023; Dr. Cecilia Wai Bing Pang ("Dr. Pang"), BBS, has been appointed as an independent non- executive director and a member of the Audit Committee, the Remuneration Committee and the Nomination Committee with effect from 21 November 2023. The biography details of Mr. Wong, Dr. Yu and Dr. Pang are set out as below: Mr. Wong, MH, aged 60, holds a master's degree in executive business administration from the Chinese University of Hong Kong. He is a fellow member of the Hong Kong Institute of Certified Public Accountants, the Institute of Chartered Accountants in England & Wales, the Association of Chartered Certified Accountants, the Hong Kong Institute of Directors and the Chartered Governance Institute.

He is also a member of the American Institute of Certified Public Accountants and a chartered member of the Chartered Institute for Securities & Investment. Mr. Wong was awarded the Medal of Honour by the Government of the Hong Kong Special Administrative Region. Mr. Wong is an independent non-executive director of Jiangxi Bank Co.

Ltd., Zhaoke Ophthalmology Limited, Kingmaker Footwear Holdings Limited (a company listed on the Stock Exchange with stock code: 1170) and C Cheng Holdings Limited. Mr. Wong served as an independent non-executive director of AEON Credit Service (Asia) Co. Ltd. from October 2004 to June 2020, Wine's Link International Holdings Limited from December 2017 to February 2023, CRCC High-Tech Equipment Corporation Limited from November 2015 to October 2022, Dongjiang Environmental Company Limited from June 2014 to December 2020, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from June 2017 to May 2023, and Inner Mongolia Yitai Coal Co.

Ltd. from May 2017 to May 2023. Save as disclosed herein, Mr. Wong did not hold any directorship in other public companies the securities of which are listed in Hong Kong or overseas in the last three years. Mr. Wong is a member of the Anhui Provincial Committee of the Chinese People's Political Consultative Conference, a panel member of Accounting and Financial Reporting Review Tribunal, a member of the Construction Industry Council, the Betting and Lotteries Commission and the Medical Council of Hong Kong as well as a board member of Ocean Park Corporation.

Mr. Wong is the managing partner and responsible officer of Hermitage Capital HK Limited, a private equity firm licensed under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO"). Prior to this, he had worked with an international audit firm for four years and then a listed company as chief financial officer for seven years, after which he co-founded Silk Road International Capital Limited (a licensed corporation formerly known as Legend Capital Partners Inc.) and led the company as the executive director and responsible officer for twenty-three years. Overall, he has over three decades of solid experience in corporate management and governance, investment management and advisory, accounting and finance.

Dr. Yu, JP, aged 69, obtained a bachelor's degree of science, a master's degree of science, and a doctoral degree of philosophy, from the University of Saskatchewan in Canada, in May 1976, October 1980 and May 1984, respectively. Dr. Yu has published more than 170 scientific papers and is the inventor of more than 70 global patents. Dr. Yu is currently an independent non-executive director, a member of the remuneration committee and a member of the nomination committee of Sirnaomics Limited.

Dr. Yu also serves as (i) a director of CR-CP Life Science Fund Management Limited since May 2021; (ii) a member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited since April 2018; (iii) a member of the board of trustees of Gordon Research Conference, a group of international scientific conferences covering biological, chemical and physical sciences and the related technologies, since July 2014; (iv) a director at Asian Fund for Cancer Research since November 2012; and (v) a member of the Technology and Innovation Subsector of the Election Committee of Hong Kong since October 2021.